Screener
Alnylam Pharmaceuticals ALNY Net product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Statements of Operations | ||||
| Revenues: | ||||
| Net product revenues | $1,172,109 | $672,212 | $2,208,236 | $1,140,750 |
| Net revenues from collaborations | 47,165 | 61,496 | 129,240 | 160,681 |
| Royalty revenue | 71,674 | 39,981 | 120,647 | 66,447 |
| Total revenues | 1,290,948 | 773,689 | 2,458,123 | 1,367,878 |
| Operating costs and expenses: | ||||
| Cost of goods sold | 298,261 | 142,029 | 505,781 | 212,212 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's net product revenues — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported net product revenues — total revenues of $1.17B in Q2 2026.
- How has Alnylam Pharmaceuticals's net product revenues — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's net product revenues — total revenues increased by 74.4% year-over-year, from $672.21M to $1.17B.
- What is the long-term trend for Alnylam Pharmaceuticals's net product revenues — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net product revenues — total revenues has grown at a 45.7% compound annual growth rate (CAGR), from $662.14M to $2.99B.
- What does net product revenues — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of commercial adoption and market penetration for the company's therapeutic portfolio. Growth in this figure reflects the successful scaling of commercialized assets and the effectiveness of the company's go-to-market strategy.
Ask your AI about Alnylam Pharmaceuticals's net product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude